Article

Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study

2021-07-19

Abstract excerpt

<h4>Background: </h4> Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or amplification pretreated with one or more system regimens, and to recommend an appropriate dose for its furth...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ada552cf-f161-5198-9a91-c24d9005e65e
DOI: 10.21203/rs.3.rs-517047/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b StudyDOI 10.21203/rs.3.rs-517047/v2Read

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.Semantic proximity Read

Antitumor Activity of Larotrectinib in Esophageal Carcinoma withNTRKGene AmplificationSemantic proximity Read

New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune CheckpointsSemantic proximity Read

Icotinib: efficacy in different solid tumors and gene mutations.Semantic proximity Read

Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.Semantic proximity Read

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma.Semantic proximity Read

Anlotinib inhibits the development of esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathwaySemantic proximity Read

Personalized targeted therapy for esophageal squamous cell carcinoma.Semantic proximity Read

Treatment patterns and Outcomes of Elderly Patients with Potentially Curable Esophageal CancerSemantic proximity Read

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.Semantic proximity Read

Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment.Semantic proximity Read

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.Semantic proximity Read